Pure Global AI
NCT06390657Not yet recruiting

Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors

EBG MedAustron GmbHClinicalTrials.govother
Verified
Study focus
Disease/Condition
Cancer
Drug/Device/Intervention
Planning CT, MRI
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
EBG MedAustron GmbH
Location
Wiener Neustadt, Austria
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Dec 01, 2025
Enrollment
20 participants
Primary outcome

Phase A: optimization of contouring and planning using PATHY strategy,Phase B: optimal coverage of Bystander tumor volume (BTV) while allowing the maximal radiation-sparing of PIM and regional lymph nodes

Summary

This study uses a novel unconventional radiotherapy technique, consisting of high dose
 PArtial Tumor irradiation targeting exclusively the HYpoxic segment of unresectable bulky
 tumors delivered either with photons (SBRT-PATHY) or with carbon-ions (CARBON-PATHY) while
 sparing the peritumoral immune microenvironment (PIM).

ICD-10 classifications
Carcinoid syndromeOther chemotherapyCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Prepuce
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06390657
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06390657 through Pure Global AI's free database. This phase not specified trial is sponsored by EBG MedAustron GmbH and is currently Not yet recruiting. The study focuses on Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.